Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Other financing activities (2024 - 2025)

Allogene Therapeutics (ALLO) has disclosed Other financing activities for 2 consecutive years, with $9.2 million as the latest value for Q4 2025.

  • Quarterly Other financing activities changed N/A to $9.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $25.3 million through Dec 2025, up 1010.0% year-over-year, with the annual reading at $6.9 million for FY2025, 202.98% up from the prior year.
  • Other financing activities hit $9.2 million in Q4 2025 for Allogene Therapeutics, roughly flat from $9.2 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $9.2 million in Q3 2025 to a low of $2.3 million in Q2 2024.